Cargando…

SARS-CoV-2 mRNA Vaccination in People with Multiple Sclerosis Treated with Fingolimod: Protective Humoral Immune Responses May Develop after the Preferred Third Shot

Evidence suggests limited development of protective IgG responses to mRNA-based vaccines in sphingosine-1-phosphate receptor (S1PR)-modulator treated individuals with multiple sclerosis (MS). We studied the extent of the humoral immune response after the preferred third mRNA SARS-CoV-2 vaccine in S1...

Descripción completa

Detalles Bibliográficos
Autores principales:	Achtnichts, Lutz, Ovchinnikov, Arkady, Jakopp, Barbara, Oberle, Michael, Nedeltchev, Krassen, Fux, Christoph Andreas, Sellner, Johann, Findling, Oliver
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8875864/ https://www.ncbi.nlm.nih.gov/pubmed/35214799 http://dx.doi.org/10.3390/vaccines10020341

Ejemplares similares

Humoral Immune Response after the Third SARS-CoV-2 mRNA Vaccination in CD20 Depleted People with Multiple Sclerosis
por: Achtnichts, Lutz, et al.
Publicado: (2021)

Long-term evaluation of NEDA-3 status in relapsing-remitting multiple sclerosis patients after switching from natalizumab to fingolimod
por: Diem, Lara, et al.
Publicado: (2018)

A comparison of balance control during stance and gait in patients with inflammatory and non-inflammatory polyneuropathy
por: Findling, Oliver, et al.
Publicado: (2018)

Correlation of disability with quality of life in patients with multiple sclerosis treated with natalizumab: primary results and post hoc analysis of the TYSabri ImPROvement study (PROTYS)
por: Achtnichts, Lutz, et al.
Publicado: (2023)

An overview of pivotal trials and real-world evidence for CD20-depleting therapy in multiple sclerosis: Immunotherapy with rituximab, ocrelizumab, and ofatumumab
por: Ovchinnikov, Arkady, et al.
Publicado: (2022)

Humoral response and safety of the third booster dose of BNT162b2 mRNA COVID-19 vaccine in patients with multiple sclerosis treated with ocrelizumab or fingolimod
por: Capuano, Rocco, et al.
Publicado: (2022)

Spike-microstates correlate with interictal epileptogenic discharges: a marker for hidden epileptic activity
por: Rochas, Vincent, et al.
Publicado: (2023)

Six-month humoral response to mRNA SARS-CoV-2 vaccination in patients with multiple sclerosis treated with ocrelizumab and fingolimod
por: Capuano, Rocco, et al.
Publicado: (2022)

Untreated anti-Ca/ARHGAP26 autoantibody-associated cerebellar ataxia progressing over 27 years
por: Schegk, E., et al.
Publicado: (2023)

SARS-CoV-2 mRNA vaccinations fail to elicit humoral and cellular immune responses in patients with multiple sclerosis receiving fingolimod
por: Meyer-Arndt, Lil, et al.
Publicado: (2022)

Tracking Multifocal Epilepsy With Automated Electric Source Imaging in a Patient With Triple-X Syndrome
por: Gschwind, Markus, et al.
Publicado: (2022)

Adaptive Immune Responses in a Multiple Sclerosis Patient with Acute Varicella-Zoster Virus Reactivation during Treatment with Fingolimod
por: Harrer, Andrea, et al.
Publicado: (2015)

Dimethyl fumarate vs fingolimod following different pretreatments: A retrospective study
por: Diem, Lara, et al.
Publicado: (2020)

Determination of Seminal Concentration of Fingolimod and Fingolimod‐Phosphate in Multiple Sclerosis Patients Receiving Chronic Treatment With Fingolimod
por: David, Olivier J., et al.
Publicado: (2017)

The Swiss Multiple Sclerosis Cohort-Study (SMSC): A Prospective Swiss Wide Investigation of Key Phases in Disease Evolution and New Treatment Options
por: Disanto, Giulio, et al.
Publicado: (2016)

Cardiac Autonomic Dysfunction in Multiple Sclerosis: A Systematic Review of Current Knowledge and Impact of Immunotherapies
por: Findling, Oliver, et al.
Publicado: (2020)

Real‐life long‐term effectiveness of fingolimod in Swiss patients with relapsing‐remitting multiple sclerosis
por: Zecca, C., et al.
Publicado: (2018)

T cells as the hoped-for savior for SARS-CoV-2 vaccination during CD20-depleting antibody therapy?: Commentary for: “Discordant humoral and T cell immune responses to SARS-CoV-2 vaccination in people with multiple sclerosis on anti-CD20 therapy.”
por: Bsteh, Gabriel, et al.
Publicado: (2021)

Humoral and Cellular Immune Response After Third and Fourth SARS-CoV-2 mRNA Vaccination in Liver Transplant Recipients
por: Harberts, Aenne, et al.
Publicado: (2022)

Recognizing myorhythmia 4 months after stroke – A teaching video
por: Finkener, Sebastian, et al.
Publicado: (2022)

Fingolimod induces neuroprotective factors in human astrocytes
por: Hoffmann, Franziska S., et al.
Publicado: (2015)

Variables Related to Working Capability among Swiss Patients with Multiple Sclerosis—A Cohort Study
por: Findling, Oliver, et al.
Publicado: (2015)

The Frog Test: A Tool for Measuring Humor Theories' Validity and Humor Preferences
por: Amir, Ori
Publicado: (2016)

Humoral and T-Cell Mediated Response after the Third Dose of mRNA Vaccines in Patients with Systemic Lupus Erythematosus on Belimumab
por: Quartuccio, Luca, et al.
Publicado: (2023)

Antidepressant activity of fingolimod in mice
por: di Nuzzo, Luigi, et al.
Publicado: (2015)

Fingolimod for Irradiation-Induced Neurodegeneration
por: Metzdorf, Judith, et al.
Publicado: (2019)

Humoral and cellular immune responses in persons with rheumatoid arthritis after a third dose of mRNA COVID-19 vaccine
por: Tedeschi, Sara K., et al.
Publicado: (2023)

Predictive factors of a viral neutralizing humoral response after a third dose of COVID-19 mRNA vaccine
por: Charmetant, Xavier, et al.
Publicado: (2022)

(347) Augmented Humoral Response to a Third And Fourth Dose of Mrna Sars-Cov-2 Vaccines in Lung Transplant Recipients
por: Kawana, S., et al.
Publicado: (2023)

Immune response to the third COVID-19 vaccine dose is related to lymphocyte count in multiple sclerosis patients treated with fingolimod
por: Achiron, Anat, et al.
Publicado: (2022)

Modulation of Cardiac Autonomic Function by Fingolimod Initiation and Predictors for Fingolimod Induced Bradycardia in Patients with Multiple Sclerosis
por: Li, Kai, et al.
Publicado: (2017)

Boosting maternal and neonatal anti–SARS-CoV-2 humoral immunity using a third mRNA vaccine dose
por: Cahen-Peretz, Adva, et al.
Publicado: (2023)

Heuristics guide the implementation of social preferences in one-shot Prisoner's Dilemma experiments
por: Capraro, Valerio, et al.
Publicado: (2014)

Longitudinal T-Cell Responses After a Third SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis on Ocrelizumab or Fingolimod
por: Palomares Cabeza, Virginia, et al.
Publicado: (2022)

Neurological safety of fingolimod: An updated review
por: Yoshii, Fumihito, et al.
Publicado: (2017)

Waning Humoral Response after COVID-19 mRNA Vaccination in Maintenance Dialysis Patients and Recovery after a Complementary Third Dose
por: Biedunkiewicz, Bogdan, et al.
Publicado: (2022)

Comparison of humoral immunogenicity in solid organ transplant recipients after third-dose mRNA vaccine with homologous or heterologous schedules: An observational study
por: Kang, Ji-Man, et al.
Publicado: (2023)

A comprehensive evaluation of humoral immune response to second and third SARS-CoV-2 mRNA vaccination in patients with malignant lymphoma
por: Suzuki, Tomotaka, et al.
Publicado: (2023)

Sex Differences in Preferences for Humor: A Replication, Modification, and Extension
por: Hone, Liana S. E., et al.
Publicado: (2015)

Fingolimod-induced decrease in heart rate may predict subsequent decreasing degree of lymphocytes
por: Ikeda, Tokunori, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_ihoad5ctm435ummbj20d0knc3k